[1]崔向勇.西格列汀联合二甲双胍治疗2型糖尿病短期疗效观察[J].新乡医学院学报,2017,34(3):212-215.[doi:10.7683/xxyxyxb.2017.03.015]
　CUI Xiang-yong.Short-term effect of sitagliptin combined with metformin in the treatment of type 2 diabetes mellitus[J].Journal of Xinxiang Medical University,2017,34(3):212-215.[doi:10.7683/xxyxyxb.2017.03.015]
点击复制

西格列汀联合二甲双胍治疗2型糖尿病短期疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
34
期数:
2017年3
页码:
212-215
栏目:
临床研究
出版日期:
2017-03-05

文章信息/Info

Title:
Short-term effect of sitagliptin combined with metformin in the treatment of type 2 diabetes mellitus
作者:
崔向勇
（新乡市第一人民医院内分泌科，河南　新乡　453002）
Author(s):
CUI Xiang-yong
（Department of Endocrinology，the First People′s Hospital of Xinxiang City，Xinxiang 453002，Henan Province，China）
关键词:
西格列汀; 二甲双胍; 血糖; C肽; 2型糖尿病
Keywords:
sitagliptin; metformin; blood glucose; C peptide; type 2 diabetes mellitus
分类号:
R587.1
DOI:
10.7683/xxyxyxb.2017.03.015
文献标志码:
A
摘要:
目的　探讨西格列汀联合二甲双胍治疗2型糖尿病（T2DM）的短期临床效果。方法　选择2012年7月至2015年7月新乡市第一人民医院收治的T2DM患者180例，按治疗方法分为二甲双胍组、西格列汀组和联合治疗组，每组60例。比较3组患者治疗前、后血糖和C肽水平，并观察患者的不良反应。结果　治疗前3组患者空腹血糖（FPG）及餐后2 h血糖（2hPPG）水平比较差异均无统计学意义（P>0.05），治疗后3组患者FPG及2hPPG水平均显著低于治疗前（P<0.05）。治疗后，联合治疗组患者FPG及2hPPG水平显著低于西格列汀组和二甲双胍组（P<0.05），西格列汀组患者FPG及2hPPG水平显著低于二甲双胍组（P<0.05）。治疗前3组患者空腹C肽及餐后2 h C肽水平比较差异均无统计学意义（P>0.05）；治疗后联合治疗组和西格列汀组患者空腹C肽及餐后2 h C肽水平显著高于治疗前（P<0.05），二甲双胍组患者治疗前、后空腹C肽及餐后2 h C肽水平比较差异均无统计学意义（P>0.05）。治疗后，联合治疗组患者空腹C肽及餐后2 h C肽水平显著高于西格列汀组和二甲双胍组（P<0.05），西格列汀组患者空腹C肽及餐后2 h C肽水平显著高于二甲双胍组（P<0.05）。二甲双胍组、西格列汀组和联合治疗组患者并发症发生率分别为5.0%（3/60）、5.0%（3/60）和3.3%（2/60），3组患者并发症发生率比较差异均无统计学意义（P>0.05）。结论　西格列汀联合二甲双胍可显著改善T2DM患者血糖及C肽水平，且安全性良好。
Abstract:
Objective　To study the short-term effect of sitagliptin combined with metformin in the treatment of type 2 diabetes mellitus（T2DM）.Methods　A total of 180 patients with T2DM were selected in the First People′s Hospital of Xinxiang City from July 2012 to July 2015.They were divided into metformin group，sitagliptin group and combined treatment group according to the treatment method，60 cases in each group.The blood glucose and C peptide levels in the three groups were compared before and after treatment，and the adverse reactions were observed.Results　There was no significant difference in the levels of fasting plasma glucose（FPG） and 2 h-postprandial blood glucose（2hPPG） in the three groups before treatment（P>0.05）.The levels of FPG and 2hPPG after treatment were significantly lower than those before treatment in the three groups （P<0.05）.After treatment，the levels of FPG and 2hPPG in combined treatment group were significantly lower than those in sitagliptin group and metformin group （P<0.05），and the levels of FPG and 2hPPG in sitagliptin group were significantly lower than those in metformin group （P<0.05）.There was no significant difference in the levels of fasting C peptide and 2 h-postprandial C peptide in the three groups before treatment （P>0.05）.The levels of fasting C peptide and 2 h-postprandial C peptide after treatment were significantly higher than those before treatment in combined treatment group and sitagliptin group （P<0.05），but there was no significant difference in the levels of fasting C peptide and 2 h-postprandial C peptide before and after treatment in metformin group（P>0.05）.After treatment，the levels of fasting C peptide and 2 h-postprandial C peptide in combined treatment group were significantly higher than those in sitagliptin group and metformin group （P<0.05），and the levels of fasting C peptide and 2 h-postprandial C peptide in sitagliptin group were significantly higher than those in metformin group （P<0.05）.The incidence of complications in metformin group，sitagliptin group and combined treatment group was 5.0%（3/60），5.0%（3/60） and 3.3%（2/60），respectively；there was no significant difference in the incidence of complications between the three groups （P>0.05）.Conclusion　Sitagliptin combined with metformin can significantly improve the blood glucose and C peptide levels in patients with T2DM，and the security is good.

参考文献/References:

［1］　石维.2型糖尿病合并动脉粥样硬化的发病机制、临床诊断与治疗［J］.中国老年学杂志，2016，36（7）：1777-1781.
［2］　王丹，郑代坤，郑胜，等.重庆市万州区2型糖尿病前期流行现状及其危险因素分析［J］.现代预防医学，2016，43（10）：1735-1738，1765.
［3］　张雷，杨世展，李承宽，等.2型糖尿病患者周围神经病变相关危险因素分析［J］.新乡医学院学报，2016，33（9）：792-794.
［4］　汪寅章.2型糖尿病临床诊断标准及口服降血糖药现状［J］.解放军保健医学杂志，1999，1（2）：1-3.
［5］　黄晶，刘安宁，陈丽灵，等.DPP-4抑制剂联合阿卡波糖治疗2型糖尿病的效果［J］.中国生化药物杂志，2016，36（1）：160-162.
［6］　刘戈力，姜丽红.儿童和青少年2型糖尿病诊治进展［J］.中华实用儿科临床杂志，2015，30（20）：1525-1528.
［7］　王霞.动态血糖监测在改善老年2型糖尿病血糖异常波动患者中的临床应用［J］.中国老年学杂志，2015，22（15）：4217-4218.
［8］　IDA S，MURATA K，BETOU K，et al.Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes：a preliminary single-arm prospective pilot study［J］.Cardiovasc Diabetol，2016，15（1）：153-161.
［9］　王滟，朱翊，孙建坤，等.西格列汀治疗老年2型糖尿病的疗效观察［J］.中国全科医学，2014，17（6）：686-688.
［10］　BONORA E，CIGOLINI M.DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus.Expectations，observations and perspectives［J］.Nutr Metab Cardiovasc Dis，2016，26（4）：273-284.
［11］　CHEN C，YU Q，ZHANG S，et al.Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes：a meta-analysis［J］.Int J Clin Exp Pathol，2015，8（11）：14141-14150.
［12］　邢颖，郑策，甄健存，等.二肽基肽酶DPP-4抑制剂-西格列汀治疗2型糖尿病的安全性国内外文献分析［J］.中国医院药学杂志，2012，32（6）：480-481.
［13］　李吉，孙家忠，李广森，等.西格列汀联合二甲双胍治疗2型糖尿病效果的系统评价［J］.中国循证医学杂志，2013，13（7）：836-843.
［14］　周鹏，金晓霞，王雪花，等.西格列汀及西格列汀与二甲双胍联合治疗2型糖尿病的临床分析［J］.临床内科杂志，2012，29（10）：676-678.
［15］　焦秀敏，许秀萍，赵晶，等.磷酸西格列汀联合二甲双胍治疗初发2型糖尿病的临床观察［J］.临床荟萃，2013，28（1）：44-45，48.

相似文献/References:

[1]高俊凤,严军,胡春平,等.二甲双胍对胰岛素抵抗小鼠肝组织中胎球蛋白A 表达及磷脂酰肌醇3-激酶/蛋白激酶B 信号通路的影响[J].新乡医学院学报,2022,39(12):1107.[doi:10.7683/xxyxyxb.2022.12.002]
　GAO Junfeng,YAN Jun,HU Chunping,et al.Effect of metformin on the expression of fetuin A and phosphatidylinositol 3-kinase/protein kinase B signal pathway in the liver tissue of insulin resistant mice[J].Journal of Xinxiang Medical University,2022,39(3):1107.[doi:10.7683/xxyxyxb.2022.12.002]
[2]张国正,连　荣,苗文杰,等.二甲双胍对变应性鼻炎小鼠炎性状态的影响[J].新乡医学院学报,2019,36(8):720.[doi:10.7683/xxyxyxb.2019.08.005]
　ZHANG Guo-zheng,LIAN Rong,MIAO Wen-jie,et al.Effects of metformin on the inflammatory state in mice with variant rhinitis[J].Journal of Xinxiang Medical University,2019,36(3):720.[doi:10.7683/xxyxyxb.2019.08.005]
[3]吕文豪,董　媛,魏子白.二甲双胍在结直肠癌治疗中的作用研究进展[J].新乡医学院学报,2021,38(7):692.[doi:10.7683/xxyxyxb.2021.07.020]
[4]崔珊珊,李雅慧,赵晨瑾,等.二甲双胍对人急性髓系白血病KG1a细胞增殖和凋亡的影响及其机制[J].新乡医学院学报,2021,38(10):901.[doi:10.7683/xxyxyxb.2021.10.001]
　CUI Shanshan,LI Yahui,ZHAO Chenjin,et al.Effect and mechanism of metformin on proliferation and apoptosis of human acute myeloid leukemia KG1a cells[J].Journal of Xinxiang Medical University,2021,38(3):901.[doi:10.7683/xxyxyxb.2021.10.001]
[5]弓慧杰,张光明.高糖环境下西格列汀对大鼠心肌细胞纤维化过程中转录激活蛋白-1及骨膜蛋白表达的影响[J].新乡医学院学报,2020,37(9):830.[doi:10.7683/xxyxyxb.2020.09.005]
　GONG Huijie,ZHANG Guangming.Effect of sitagliptin on the expression of transcriptional activator-1 and periostinin in the process of cardiomyocyte fibrosis under the environment of high sugar[J].Journal of Xinxiang Medical University,2020,37(3):830.[doi:10.7683/xxyxyxb.2020.09.005]
[6]崔向勇.达格列净联合二甲双胍治疗2型糖尿病肾病疗效观察[J].新乡医学院学报,2022,39(4):362.[doi:10.7683/xxyxyxb.2022.04.013]
　CUI Xiangyong.Effect of dapagliflozin combined with metformin in the treatment of patients with type 2 diabetic nephropathy[J].Journal of Xinxiang Medical University,2022,39(3):362.[doi:10.7683/xxyxyxb.2022.04.013]
[7]姜　宁,路　平.二甲双胍抗肿瘤作用机制[J].新乡医学院学报,2016,33(2):150.[doi:10.7683/xxyxyxb.2016.02.020]
　JIANG Ning,LU Ping.Anti tumor mechanism of metformin[J].Journal of Xinxiang Medical University,2016,33(3):150.[doi:10.7683/xxyxyxb.2016.02.020]
[8]张晓辉,张弛,刘浩钦.2型糖尿病患者合并甲状腺功能减退症的危险因素分析[J].新乡医学院学报,2023,40(3):234.[doi:10.7683/xxyxyxb.2023.03.007]
　ZHANG Xiaohui,ZHANG Chi,LIU Haoqin.Analysis of risk factors of hypothyroidism in patients with type 2 diabetes mellitus[J].Journal of Xinxiang Medical University,2023,40(3):234.[doi:10.7683/xxyxyxb.2023.03.007]

更新日期/Last Update: 2017-03-05